The clinical use of anticancer anthracyclines is limited by the development of a distinctive and life-threatening form of cardiomyopathy upon chronic treatment. Commonly accepted mechanistic hypotheses have assigned a pivotal role to iron, which would act as a catalyst for free radical reactions and oxidative stress. Although perhaps involved in acute aspects of anthracycline cardiotoxicity, the role of free radical-based mechanisms in long-term effects has been challenged on both experimental and clinical grounds, and alternative hypotheses independent of iron and free radicals have 
I. BACKGROUND
Since its isolation from Streptomyces peucetius some 30 years ago, doxorubicin (DOX; former generic name, adriamycin) 2 has proved remarkably useful in the clinical management of carcinomas, sarcomas, and lymphomas. Unfortunately, long-term treatment with DOX and other extractive or pharmaceutically engineered anthracyclines is limited by acute and chronic cardiotoxicity. Whereas the acute toxicity presents with transient and clinically manageable arrhythmias and hypotension, the chronic toxicity can insidiously evolve into congestive heart failure, which is refractory to standard inotropic medications (1) . Chronic cardiomyopathy and heart failure may develop any time after completion of anthracycline regimens, and occur more frequently in patients given cumulative doses of DOX above 550 mg/m 2 (1) . According to the prevailing hypothesis, the cardiotoxicity of anthracyclines is mediated by mechanisms that are distinct from those underlying the antitumor effects of these drugs, i.e., DNA intercalation and interference with the catalytic cycle of DNA topoisomerase II (2) . A major role in the development of cardiotoxicity has been assigned to iron, presumably because this metal can catalyze free radical reactions that overrule the antioxidant defenses of cardiomyocytes. Elegant reviews and editorials in this (3) (4) (5) and other journals (2, 6 -8) have contributed to the popularity of such hypothesis; however, there have also been reports showing that the 'iron and free radical hypothesis' of cardiotoxicity does not withstand scrutiny according to some biochemical or pharmacological criteria (4, 9, 10) . Hence, some investigators have proposed mechanisms of cardiotoxicity that are independent altogether of both iron and free radicals (4) . In an attempt to bridge the two extremes of this field, other studies have maintained a role for iron but not for free radicals, suggesting that anthracycline cardiotoxicity reflects disturbances in iron homeostasis within cardiomyocytes rather than the outcome of iron-catalyzed free radical injury (11, 12) . The aim of 1 Correspondence: G. D'Annunzio University School of Pharmacy, Institute of Drug Sciences, Department of Pharmacology and Pharmacognosy, Via dei Vestini, 66013 Chieti, Italy. E-mail: gminotti@unich.it 2 Abbreviations: DOX, doxorubicin; DOXol, doxorubicinol; O 2 ⅐Ϫ , superoxide anion; H 2 O 2 , hydrogen peroxide; low mol wt, low molecular weight; ⅐ OH, hydroxyl radical; Fe IV ϭO, ferryl ion; SOD, superoxide dismutase; PBN, N-tertbutyl-␣-phenylnitrone; POBN, ␣-(4-pyridyl-1-oxide)-N-tert-butylnitrone; DMPO, 5,5-dimethyl-1-pyrroline N-oxide; MT, metallothionein; TfR, transferrin receptor; IRP, iron regulatory protein; IREs, iron-responsive elements; TEMPOL, 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl.
this review is to weigh biochemical and pharmacological arguments for and against the aforementioned hypotheses.
II. DOES IRON MEDIATE ANTHRACYCLINE CARDIOTOXICITY? STUDIES WITH CHELATORS SEEM TO SAY YES
The possible involvement of iron in anthracyclineinduced cardiotoxicity first emerged in the middle 1970s, when a series of nonpolar derivatives of EDTA, including a bis-ketopiperazine code-named ICRF-187 and subsequently given the nonproprietary name of dexrazoxane-were shown to prevent the cardiac lesions and dysfunction induced by anthracyclines in both isolated heart models and whole animals (13) . A role for iron has been maintained ever since and has been made increasingly appealing by several pieces of evidence. For example, electron paramagnetic studies have shown that mitochondrial, nuclear, and microsomal reductases catalyze one-electron addition to the quinone moiety of the tetracycline ring of anthracyclines. This results in the formation of a semiquinone free radical that readily regenerates the parent quinone by reducing molecular oxygen to superoxide anion (O 2 ⅐Ϫ ) and its dismutation product hydrogen peroxide (H 2 O 2 ), increasing these species above the physiologic levels generated during normal aerobic metabolism (6) . Both O 2 ⅐Ϫ and H 2 O 2 have their inherent toxicity, but cell damage ensues more rapidly when they react with low molecular weight (low mol wt) iron (14) . To prevent toxic interactions of iron with physiologic or pathologic sources of O 2 ⅐Ϫ and H 2 O 2 , cells have evolved ferritin, a 24 subunit protein in which iron is safely stored as polynuclear ferric oxohydroxide (15) . Such a protective mechanism of iron segregation can be overcome by O 2 ⅐Ϫ , which is small enough to penetrate the transprotein channels of ferritin and has a reduction potential lower than that of ferritin-bound iron. It follows that O 2 ⅐Ϫ has both sterical and thermodynamic requisites to reductively release iron from ferritin (16) . Anthracycline semiquinones are too large to penetrate ferritin; however, they can release iron by virtue of electrontunneling mechanisms, which are relayed by redox sites located on the surface and transprotein channels of ferritin (16) . This latter mechanism can actually be more efficient than that mediated by O 2 ⅐Ϫ ; in fact, chemical studies have shown little or no interference by superoxide dismutase (SOD) with the ability of DOX to delocalize Fe(II) (17, 18) . DOX can also form iron complexes that redox-cycle between ferrous and ferric forms by donating electrons to oxygen or by drawing reducing equivalents from either glutathione or the side chain C-14 primary alcohol of the anthracycline itself, respectively (3). These iron complexes probably contribute to the redox effect of DOX on cardiomyocytes.
On the whole, one-electron redox cycling of anthracyclines increases the intracellular levels of both low mol wt Fe(II) and H 2 IV ϭO can eventually cause cardiac dysfunction by oxidizing lipids, proteins, and DNA, perhaps in concert with the redox activity of DOX-iron complexes (Fig. 1) .
In most cells, the chances for Fe(II) to form ⅐ OH or Fe IV ϭO are kept to a minimum by the presence of detoxifying enzymes that concur in reducing O 2
⅐Ϫ
and H 2 O 2 to water (SOD, catalase, and glutathione peroxidase). Consistent with the 'iron and free radical hypothesis', cardiomyocytes are ill equipped with these enzymes and thus may provide the ideal scenario for the formation of ⅐ OH or Fe IV ϭO (5, 6). Moreover, the earliest ultrastructural changes induced by DOX involve mitochondria and sarcoplasmic reticulum, as would be expected based on the presence in these organelles of NADH dehydrogenase or NADPH-cytochrome P450 reductase, respectively, which reduce DOX to semiquinone free radical (4, 6) . Dexrazoxane can protect against oxidative damage by entering cardiomyocytes and by undergoing stepwise hydrolysis of the two piperazine rings. This process releases one-and two-open ring byproducts that chelate free iron or divert it from potentially toxic interactions with DOX (19, 20) . Initial studies in laboratory animals showed that dexrazoxane had unique pharmacokinetic, pharmacodynamic, and toxicologic properties. First, it did not interfere with anthracycline distribution, metabolism, or excretion (21), nor did it appear to mitigate the antitumor potency of anthracyclines (22) . Second, it imposed relatively limited damage on mitotically active tissues such as bone marrow, testes, and gastrointestinal epithelia (23) . Finally, it protected against both acute and chronic cardiotoxicity in all the animal models tested, ranging from mice to dogs or swine (8) . These findings were largely confirmed in clinical trials showing that dexrazoxane could decrease the incidence or severity of anthracycline cardiotoxicity without affecting objective tumor response (24) . At longer follow-up, dexrazoxane also allowed patients to receive significantly greater cumulative doses of DOX without increasing its cardiotoxicity, the only drawback being a moderate to severe exacerbation of myelosuppression (25) . How-ever, more recent studies have raised the possibility that dexrazoxane decreases tumor response in breast cancer patients treated with DOX (26) . These clinical findings appear to validate in vitro studies showing that dexrazoxane antagonizes the apoptotic and antiproliferative effects of DOX (27, 28) , presumably by interfering with anthracycline-topoisomerase II interactions (29) . Such interference is mediated by intact dexrazoxane but not by its hydrolysis products, indicating that a mechanism(s) other than iron chelation and prevention of free radical events may be involved (30) .
III. DOES IRON MEDIATE ANTHRACYCLINE CARDIOTOXICITY BY CATALYZING FREE RADICAL REACTIONS? STUDIES WITH ANTIOXIDANTS YIELD INCONCLUSIVE EVIDENCE
The 'iron and free radical hypothesis' of cardiotoxicity has been tested with a variety of compounds endowed with antioxidant properties. Thus, laboratory animals have been treated with vitamin E, N-acetylcysteine, or coenzyme Q 10 , a nutritional cofactor with the dual advantage of acting as an antioxidant while participating in the mitochondrial electron transport chain involved in ATP production. All these compounds have yielded encouraging results in murine models of acute or chronic anthracycline cardiotoxicity, as indicated by suppression of biochemical indices of oxidative damage, e.g., lipid peroxidation (8) . Excellent results have likewise been obtained with probucol, a compound initially developed as a lipid-lowering drug. Due to the presence of two phenolic groups in its molecule, probucol inhibits lipid peroxidation and affords protection in a mouse model of chronic cardiotoxicity without affecting the antitumor efficacy of the anthracycline (31) . Moreover, probucol can provide protection by increasing intracardiac levels of SOD, catalase, and glutathione peroxidase, both per se and in combination with DOX (32) .
One additional strategy to probe and possibly counteract the role of free radicals in small animal models of anthracycline cardiotoxicity has relied on the use of low mol wt spin trapping agents such as N-tert-butyl-␣-phenylnitrone (PBN), ␣-(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN), and 5,5-dimethyl-1-pyrroline N-oxide (DMPO). The rationale for using these compounds has been twofold. The ability of spin traps to form stable adducts with free radicals in intact tissues or cell-free systems, thus allowing their detection by electron paramagnetic spectroscopy, strongly suggested that they might prevent anthracycline cardiotoxicity if free radicals were involved in the process. On the other hand, spin traps can intercept both oxygen-and carbon-centered radicals, and thus may prove to be more versatile and effective protectants than other antioxidants. As expected from these biochemical premises, spin traps were found to protect atria and whole heart preparations from DOX-induced mechanical dysfunction (33) . The degree of protection achieved has been found to correlate with the lipophilicity of these compounds, being highest with PBN, followed by POBN and DMPO (CHCl 3 /H 2 O partition coefficients at 24°C: 199.0, 1.19, and 0.13, respectively) (34) . Comparative studies of DMPO vs. PBN have also shown that the former distributes almost exclusively within the cytosolic compartment, whereas PBN can also be found in mitochondria. The higher efficacy of PBN, subsequently confirmed by in vivo studies (35) , could thus be explained by its ability to achieve substantial levels at the very sites where DOX bioactivation initiates a cascade of free radical reactions.
Research groups have recently readdressed the role of free radicals by evaluating the in vivo cardiotoxicity of DOX in transgenic mice overexpressing antioxidant defense systems. Such studies focused mainly on myocardial overexpression of catalase (36) and mitochondrial MnSOD (37) or the thiolrich nonenzymatic protein metallothionein (MT), which has been shown to effectively scavenge ⅐ OH and to act as an iron chelator in vitro (38, and references therein). The transgenic mouse model was designed to elude the shortcomings due to poor cell penetration of exogenously administered proteins and to guarantee high catalase, MnSOD, and MT activity inside the cardiomyocytes. All three approaches proved successful in reducing acute myocardial damage by DOX, as assessed by ultrastructural lesions, intracellular enzyme release, and functional impairment. Although the transgenic approach may be impractical for clinical purposes, it clearly indicates that stable increases in intramyocardial levels of antioxidant proteins may effectively protect the heart from DOX, at least in small animal models of anthracycline cardiotoxicity.
Whereas the effects of antioxidants in rats and mice or in in vitro models of cardiotoxicity have lent credibility to the free radical hypothesis, similar studies in large animals have produced contrasting notions, especially when chronic anthracycline regimens were adopted. Although not all of the cardioprotective strategies outlined above have been tested in large animal models of anthracycline cardiotoxicity, carefully designed experiments with N-acetylcysteine or vitamin E have shown that neither compound would prevent or significantly reduce cardiac lesions induced by chronic treatment of dogs with DOX (23, 39) . Similar negative results have been obtained in clinical trials in which patients were given vitamin E (40) or N-acetylcysteine (41) prior to and/or concomitant with DOX. In none of these trials could antioxidants prevent cardiac dysfunction associated with multiple doses of the anthracycline. In the case of vitamin E, an intensified regimen was started as early as a week prior to DOX treatment, increasing the serum levels of this antioxidant by sixto eightfold. Such vigorous and pharmacokinetically optimized treatment was nonetheless insufficient to prevent heart failure and ultrastructural changes at endomyocardial biopsy (40) . To better appraise these negative findings, one should keep in mind that lesser increases in vitamin E plasma levels are sufficient to prevent or decrease the incidence of other cardiac events that presumably involve oxidative stress, such as nonfatal myocardial infarction in patients with coronary atherosclerosis (42), arrhythmias and reinfarction after aortocoronary bypass (43) , and fatal infarction in smokers (44) .
In summary, chelating iron with dexrazoxane mitigates both acute and chronic cardiotoxicity, and such protection can be seen in patients as well as in all the animal models tested. In contrast, antioxidant interventions afford protection in small animals, but not in patients or large animals at risk for chronic cardiomyopathy. This discrepancy raises a potentially critical issue that needs to be addressed from mechanistic and pathophysiologic viewpoints.
IV. DO ANTHRACYCLINES GENERATE TOO MANY RADICALS FOR THEM TO MEDIATE CARDIOTOXICITY?
To explain the lack of protection by antioxidants, one might argue that free radical processes are more a consequence than a cause of tissue damage; hence, antioxidants would interfere with second-line reactions having little relevance to the etiology of cardiomyopathy. This issue has been brought into focus by several authors, especially with regard to lipid peroxidation (45) . Another possibility is that anthracyclines form too many radicals, setting the stage for radical-radical interactions that eventually extinguish oxidative stress. For example, semiquinone free radicals might terminate lipid peroxidation by preferentially interacting with lipid radical species rather than with oxygen or iron (46 (16) . Studies in microsomal systems (50) or cell cultures (51) exposed to DOX suggest that this may be the case. In these systems, lipid peroxidation and other indices of damage were significantly enhanced by addition of catalase or by genetic manipulations leading to catalase overexpression, respectively, as would be expected if excess H 2 O 2 were negating moderate oxidation of Fe(II) with oxygen and consequent formation of optimal Fe(II)/Fe(III) ratios. Keeping these mechanisms in mind, one might conclude that antioxidants cannot protect against cardiotoxicity for the very reason that anthracyclines possibly prevent, rather than induce, oxidative damage. Studies in isolated heart models or in whole animals (reviewed in ref 4) appear to validate these conclusions, showing that cardiotoxicity may sometimes develop in the absence of lipid peroxidation or other indices of oxidative damage. Such a possibility is more difficult to prove in patients, as both ethical and practical constraints preclude biochemical measurements of oxidative stress in fine needle myocardial biopsies. To overcome these problems, cardiac lipid peroxidation has been assessed by collecting blood samples from the coronary sinus and by measuring the plasma levels of lipid conjugated dienes and hydroperoxides before and after DOX infusions. These studies have shown that DOX does not increase but actually decreases the myocardial release of conjugated dienes and hydroperoxides, apparently confirming that a free radical-generating drug can paradoxically abolish oxidative damage (10).
These new findings call for a critical reassessment of previous studies supporting the oxidative nature of anthracycline cardiotoxicity, especially regarding the transgenic mice models. For instance, one would expect overexpression of MnSOD to increase the dismutation of O 2 ⅐Ϫ without significantly affecting iron delocalization by semiquinone free radicals, thus increasing the availability of H 2 O 2 for reaction with Fe(II) and formation of ⅐ OH or Fe IV ϭO. Nevertheless, cardiac damage is halted by MnSOD overexpression (37) , suggesting that 1) neither ⅐ OH nor Fe IV ϭO contribute to toxicity, and 2) tissue damage probably is mediated by iron-oxygen complexes, which become redox-inactive when excess dismutation of O 2 ⅐Ϫ to H 2 O 2 shifts Fe(II)/Fe(III) ratios toward unreactive Fe(III). Similar considerations can be extended to the catalase studies. In fact, cardiac lipid peroxidation was suppressed at catalase expression levels approaching values 100-fold over the wild-type; however, higher levels of catalase expression did not prevent, but actually enhanced, lipid peroxidation (36) . While indicating that catalase overexpression provides a very narrow window of protection, these studies indirectly confirm that free radical injury is promoted when Fe(II) is 'protected' from excessive oxidation by H 2 O 2 , which presumably occurs at very high levels of enzyme expression. On balance, the results obtained with SOD-or catalase-overexpressing mice are open to debate and do not provide unequivocal evidence that anthracycline cardiotoxicity is indeed mediated by oxidative processes.
V. IS ANTHRACYCLINE CARDIOTOXICITY INDEPENDENT OF IRON AND FREE RADICALS?
The last decade has witnessed the identification of cardiotoxicity mechanisms that do not implicate free radicals as causative agents. Several studies along this line of research have shown that DOX can activate signal transduction pathways that disrupt the cardiac gene expression program. DOX decreases the intracardiac levels of mRNAs for several important proteins and enzymes (52) (53) (54) (55) , which may account for both morphologic and functional features of chronic cardiotoxicity ( Table 1) . The effects of DOX on mRNAs are independent of free radicals (56) and are considerably less evident at extracardiac sites, possibly because such effects are mediated by transcriptional regulatory proteins expressed selectively in cardiomyocytes (e.g., the so-called cardiac adriamycin-responsive protein/CARP) (57) . Alternative mechanisms of cardiotoxicity have implicated DOX metabolites other than semiquinone free radicals. This is the case for doxorubicinol (DOXol), a hydroxy metabolite formed upon twoelectron reduction of the C-13 carbonyl group in the side chain of DOX:
DOXol is formed by cytosolic NADPH-dependent enzymes sharing similarities with the multigene family of carbonyl and aldo-keto reductases (58) . From a pharmacokinetic standpoint, DOXol accumulates in the heart of rats receiving multiple DOX injections; such accumulation reflects intramyocardial DOX metabolism rather than metabolite uptake from the bloodstream (4). This has suggested that the delayed cardiotoxicity induced by chronic treatment with DOX in laboratory animals may reflect a unique tendency of cardiomyocytes to form and retain DOXol. This also seems to occur in DOX-treated patients, as limited studies in postmortem tissues have demonstrated that DOXol can be detected within cardiomyocytes well after completion of anthracycline treatments (59) . Experiments in ex vivo samples, obtained from patients undergoing aortocoronary bypass grafting, have confirmed that human cardiomyocytes can reduce DOX to DOXol by virtue of cytosolic aldo-keto reductases (11) . From a pharmacodynamic viewpoint, the C-13 secondary alcohol moiety of DOXol is redox-inactive toward oxygen and thus is unable to initiate a free radical cascade. Nonetheless, DOXol can potently and directly inhibit the Ca 2ϩ -Mg 2ϩ ATPase of sarcoplasmic reticulum, the f 0 -f 1 proton pump of mitochondria, and the Na ϩ -K ϩ ATPase and Na ϩ -Ca 2ϩ exchanger of sarcolemma (60, 61) . DOXol can therefore affect myocardial energy metabolism, ionic gradients, and Ca 2ϩ movements, ultimately impairing cardiac contraction and relaxation.
By rationalizing anthracycline cardiotoxicity as a free radical-independent disease, the two mechanisms described above may explain why antioxidants cannot protect patients or large animals. At the same time, these mechanisms are difficult to reconcile with the protective efficacy of dexrazoxane (8) 
Inasmuch as these two possibilities remain unverified at the present time, one can only conclude that anthracycline cardiotoxicity is a multifactorial process involving both iron-independent and iron-mediated processes. It would also appear that the role of iron cannot be confined to the promotion of free radical events, as not only dexrazoxane, but also antioxidants would protect patients or large animals if this were the case. To better appraise the role of iron, one should probably address the following questions. Can anthracyclines perturb the mechanisms whereby iron is handled as an essential cofactor rather than as a free radical catalyst? Further, can dexrazoxane antagonize the effect of DOX on iron homeostasis and related cell functions?
VI. THE IRP-IRE MACHINERY: A KEY MECHANISM OF IRON HOMEOSTASIS AND A NOVEL TARGET OF ANTHRACYCLINE CARDIOTOXICITY
Cellular iron homeostasis relies on the concerted action of the transferrin receptor (TfR) and ferritin. The former mediates iron uptake by internalizing iron-laden transferrin (63); the latter stores iron in excess of the metabolic requirements of the cell (64) . Both TfR and ferritin can be regulated at a transcriptional level (65), but a major regulatory mechanism occurs posttranscriptionally (66 -68) . This involves interaction of iron regulatory protein (IRP) -1 with specific motifs in the 5Ј untranslated region of ferritin mRNA and in the 3Ј end of TfR mRNA. These are the so-called iron-responsive elements (IREs), highly conserved sequences with the potential to assume a stem-loop structure. When cells need iron, IRP-1 binds to IREs in TfR mRNA, protecting the transcripts from degradation (68); at the same time, IRP-1 interacts with IREs in ferritin mRNA and blocks translation by sterically preventing the binding of translation initiation factors (69) . These divergent but coordinate actions of IRP-1 cause iron uptake by TfR to prevail over iron sequestration by ferritin, thus yielding a pool of low mol wt iron readily available to meet metabolic requests. Conversely, high iron levels decrease the IRE binding activity of IRP-1, leading to efficient translation of ferritin mRNA and increased degradation of TfR mRNA. Thus, IRP-1 links ferritin and TfR levels to cellular iron status.
Definition of the structure of IRP-1 provided a clue to understanding how this protein can sense iron levels. IRP-1 is the cytosolic counterpart of mitochondrial aconitase, the enzyme that isomerizes citrate into isocitrate in the Krebs cycle by virtue of a catalytic [4Fe-4S] cluster (70) . When cells are iron depleted, the [4Fe-4S] cluster is disassembled and the cytosolic aconitase switches to IRP-1; when cells are iron repleted, the cluster is reconstituted and IRP-1 switches back to aconitase (66 -68) (Fig. 2) . The ϪSH groups of several cysteine residues have been implicated in RNA binding or cluster iron coordination, but only Cys 437 appears to participate in both processes (71) . Anthracyclines have the potential to disrupt this simple but highly efficient mechanism of iron homeostasis. In fact, recent studies from our laboratories have shown that reconstitution of DOXol with cytosolic fractions from human myocardial samples causes delocalization of low mol weight Fe(II) from the [4Fe-4S] cluster of aconitase (12) . This reaction proceeds via redox mechanisms, which regenerate DOX and form DOX-Fe(II) complexes as ultimate by-products; the latter can, in turn, inhibit IRP-1 and prevent its physiologic switch to aconitase (12) . Sulfydryl reductants like ␤-mercaptoethanol cannot rescue either IRP-1 or aconitase activities, and this implies that DOX-Fe(II) complexes can irreversibly modify Cys 437 to sulfinic/ sulfonic derivatives that cannot be converted back to ϪSH (12) . Although in vitro (68, 72) and in vivo (73) studies have implicated O 2 ⅐Ϫ and H 2 O 2 as pathophysiologic modulators of aconitase/IRP-1, neither SOD nor catalase appear to protect this protein from the action of DOXol (12) . These findings confirm that C-13 metabolites can cause cardiac damage by virtue of oxyradical-independent mechanisms.
Besides IRP-1, cells may contain an IRP-2 with similar binding affinity and specificity to consensus IREs (68, 74) . However, IRP-2 cannot form [4Fe-4S] clusters and hence cannot sense iron levels by switching between aconitase and IRE binding activities, as does IRP-1. The mechanism whereby IRP-2 contributes to iron homeostasis is regulated by its ubiquitination and proteasome-mediated degradation (75) . When iron is abundant, IRP-2 is degraded; when iron is scarce, IRP-2 is protected from degradation and can bind to IREs, leading to up-regulation or down-regulation of TfR or ferritin mRNA translation, respectively. A unique 73 amino acid sequence serves as the degradation domain of IRP-2 (75). Currently available techniques do not always allow the separation of IRP-1 from IRP-2 in human samples; hence, we do not know whether DOXol inactivation of aconitase/IRP-1 is accompanied by a simultaneous loss of IRP-2. However, binding of IRP-2 to mRNAs is mediated by cysteine residues that are particularly susceptible to chemical modifications, similar to the cysteines of IRP-1 (76) . It is therefore conceivable that the DOX-Fe(II) complexes that inactivate IRP-1 can do the same with IRP-2.
What are the pathologic consequences of disrupting the IRP/IRE machinery? Broadly speaking, one can expect that cardiomyocytes become unable to sense iron levels and to coordinate iron trafficking between transferrin receptor, ferritin, and the different sites of iron metabolic use. Disruption of the IRP/IRE machinery might also affect posttranscriptional processes and metabolic events not immediately related to the TfR-ferritin pathway. This is suggested by the presence of IRE motifs in the 5Ј regions of mRNAs for mitochondrial aconitase, Drosophila succinate dehydrogenase, and erythroid ␦-aminolevulinate synthase (68), as well as in the 3Ј region of mRNA for mammalian proton-coupled metal ion transporters (e.g., DCT1/Nramp2) (77) . The effect of IRP-1 modifications on cellular iron homeostasis has indeed been demonstrated by several studies. Cells overexpressing iron-insensitive IRP-1 mutants cannot withstand iron supplementation (78) , and inappropriately high IRP activity has been been found in duodenal (79) or reticuloendothelial cells (80) from iron overload-prone hemochromatosis patients. In contrast, low IRP activity has been found in monocytes from patients with inflammation, providing a mechanistic link between enhanced iron sequestration in the reticuloendothelial system, reduced iron availability for hematopoiesis, and persistent anemia in chronic diseases (81) .
By disrupting cardiac iron homeostasis, the decline in IRP activity would also lead to inadequate reconstitution of several enzymes and oxygen binding proteins that function by virtue of this metal (cytochromes, catalase, lipoxygenases, myoglobin, etc.). Additional consequences of DOXol/IRP interactions might be expected after misplacement of iron ions at cellular sites critical to the contractionrelaxation cycle. This is best exemplified by recent studies showing that chronic anthracycline treatment desensitizes sarcoplasmic reticulum to Ca 2ϩ -induced Ca 2ϩ release, indicating a dysfunction of the Ca 2ϩ -gated/ryanodine receptor-2 Ca 2ϩ release channel (82) . Whereas anthracycline treatment definitely decreases the levels of channel mRNA (55) and immunoreactive proteins (83), a corollary mechanism for channel dysfunction has been identified in its sterical occupancy by iron ions. In this context, Fe(II) is remarkably more inhibitory than Fe(III), presumably because it has greater affinity for the cysteine residues lining the channel (84) . Collectively, these studies suggest that Ca 2ϩ channels and IRPs share similar mechanisms of inactivation by Fe(II) and foretell that changes in the IRP/IRE machinery may lead to anomalous iron movements and sterical association with cell constituents other than storage proteins or iron-dependent enzymes.
The 'IRP/IRE hypothesis' of cardiotoxicity has two additional convincing pros. First, the cardiotoxicity scores of structurally distinct anthracyclines correlate better with the intracardiac formation of C-13 metabolites than with systemic metabolism and disposition (11) . This suggests that the cardiotoxic potential of anthracyclines might be reliably predicted from their affinity for myocardial aldo-keto reductases, regardless of drug-to-drug variability in extracardiac pharmacokinetics. Second, the 'IRE-IRP hypothesis' may help clarify the role of dexrazoxane from novel standpoints. Dexrazoxane might protect cardiomyocytes by competing with DOX for iron and preventing formation of those drug-iron complexes that inactivate aconitase/ IRP-1 and, perhaps, IRP-2, as previously hinted. In so doing, dexrazoxane can mitigate disturbances in iron movements, metabolic use, and sterical association with proteins or enzymes. In either case, dexrazoxane would act on homeostatic processes rather than free radical reactions, possibly explaining why antioxidant interventions are less protective than chelation therapy against chronic cardiotoxicity. The IRE/IRP hypothesis of cardiotoxicity nonetheless has its drawbacks. For example, there have been sporadic reports of delayed cardiotoxic effects in laboratory animals after a single DOX administration, in spite of the fact that DOXol accumulates to a minimal extent under these conditions and eventually disappears within a week after drug treatment (85) . Again, studies in laboratory animals have shown that 5-iminodaunorubicin can form a C-13 hydroxy metabolite and yet is less cardiotoxic than other anthracyclines (86, 87) . Inasmuch as the C-13 derivatives from structurally distinct anthracyclines have been shown to retain comparable iron reactivity (11), it is unlikely that the reduced cardiotoxicity of 5-iminodaunorubicin may be attributed to decreased interactions of its hydroxymetabolites with aconitase/ IRPs or other targets. What is peculiar to 5-iminodaunorubicin is that its quinone moiety has been chemically modified so as to generate much less O 2 ⅐Ϫ and H 2 O 2 (86, 87) . This suggests that anthracyclines can be made less cardiotoxic by decreasing generation of oxyradicals rather than of C-13 metabolites, in the face of conceptual efforts to identify mechanisms alternative to oxidative stress! Although the clinical use of 5-iminodaunorubicin has been precluded by severe extracardiac toxicity, preclinical evidence accumulated with this drug clearly argues against the DOXol and IRE/IRP hypothesis.
VII. ROLE OF IRON IN ANTHRACYCLINE CARDIOTOXICITY: IS THERE ROOM FOR A UNIFYING HYPOTHESIS?
To elucidate the role of iron in anthracycline cardiotoxicity, we have reviewed mechanisms that either implicate this metal as a catalyst of oxidative damage or envision possible disturbances of its metabolic use. Neither mechanism can satisfactorily encompass the experimental and clinical aspects of anthracycline cardiotoxicity, and the reason for this may be twofold. First, anthracycline cardiotoxicity is a multifactorial event in which iron-based reactions are accompanied by equally important iron-independent processes. Second, the involvement of iron in oxidative damage or metabolic disturbances must be preceded by one-or two-electron reduction of anthracyclines to semiquinone free radicals or C-13 hydroxy derivatives, respectively. Inasmuch as these metabolites are formed by different reductases at different cell sites, the way iron intervenes in cardiotoxicity may vary with time and reflect more than one mode of action.
A key to a unifying hypothesis might be to separate the mechanism(s) of acute cardiotoxicity from those of chronic cardiomyopathy and to see whether the former can be preparatory to the latter. As for the acute cardiotoxicity, biochemical indices of oxidative damage and effective protection by both antioxidants and dexrazoxane indicate that, with the possible exception of few experimental conditions (4), ironcatalyzed free radical injury is important in this setting. As mentioned, this is more difficult to prove in patients, who respond to acute DOX treatments with a paradoxical inhibition of cardiac lipid peroxidation rather than with stimulation (10). This is a unique situation, perhaps because cancer patients present with spontaneously up-regulated prooxidant tone and react to DOX metabolism and H 2 O 2 formation with unproductive processes that annihilate ⅐ OH or iron-oxygen complexes (cf. Section IV and ref 10) .
As anthracyclines are given chronically, depletion of antioxidant defenses such as glutathione and related enzymes (4) and the consequent accumulation of H 2 O 2 may likewise divert ⅐ OH from oxidative damage or inactivate iron-oxygen complexes, thereby terminating free radical injury. The transition from acute to chronic effects is therefore accompanied by a decline of the protective efficacy of antioxidants but not of dexrazoxane, perhaps because this is the time when iron moves from the free radical arena to the homeostatic disorders associated with DOXol formation and consequent inactivation of the IRE/IRP machinery (Fig. 3) . Can this hypothesis incorporate a mechanistic link between acute and chronic cardiotoxicity? We propose that it can. In fact, recent studies in smooth muscle cells have shown that aldo-keto reductase induction may represent a common response in tissues exposed to H 2 O 2 and certain by-products of lipid peroxidation (e.g., 4-hydroxy-nonenal) (88) . Whereas the induction of these enzymes enables cells to detoxify lipid aldehydes formed during the acute phase of cardiotoxicity, it also paves the road to time-delayed reduction of DOX to DOXol and consequent inactivation of IRPs. Thus, chronic cardiotoxicity might be 'primed' by events occurring at earlier stages, such as the redox cycling of anthracyclines with oxygen (yielding H 2 O 2 ) and the promotion of iron-catalyzed damage (causing lipid peroxidation) (cf. Fig. 3 ). Direct evidence for anthracycline induction of aldoketo reductases is lacking, but the observation that intracardiac levels of DOXol increase with time and repeated dosing of DOX strongly indicates that this may be the case.
Our hypothesis may also help address two additional questions. The first question is: Can ironindependent mechanisms exacerbate the iron-based ones? Again, we propose that it can. For example, free radicals generated during the acute phase of cardiotoxicity might damage nucleic acids without causing overt cardiac dysfunction until myocytes fail to repair or replace important enzymes and proteins with low turnover rates (35) . The ability of DOX to concomitantly disrupt cardiac gene expression in an iron-independent fashion might definitely exacerbate this pathway of cardiotoxicity. Likewise, the ability of DOXol to directly inhibit constitutive or de novo synthesized enzymes would amplify the consequences of free radical-mediated DNA damage and free radical-independent impairment of gene expression (Fig. 3) .
The second question to be answered is: Can our unifying hypothesis explain the decreased cardiotoxicity of 5-iminodaunorubicin and reconcile this with the DOXol and IRE/IRP story? We propose that positive answers can be given with respect to both acute and chronic cardiotoxicity mechanisms. Due to chemical modifications at the quinone moiety, 5-iminodaunorubicin cannot reduce oxygen nor can it delocalize iron from cellular stores; therefore, it clearly fails to promote iron-and free radical-dependent acute toxicity. Because of its lower redox activity, 5-iminodaunorubicin might similarly fail to link the acute toxicity to the free radical-independent phase of cardiac damage, as the latter must be 'prepared' by H 2 O 2 or lipid aldehyde induction of the aldo-keto reductases that form C-13 metabolites. The lower toxicity of 5-iminodaunorubicin can thus be reconciled with both free radical-independent and -dependent mechanisms.
VIII. NOVEL HYPOTHESES CAN HELP DESIGN BETTER PROTECTIVE STRATEGIES
As mentioned, the clinical usefulness of dexrazoxane is limited by moderate to severe exacerbation of myelotoxicity as well as by possible interference with the antitumor efficacy of DOX. Therefore, the need for high-dose and long-term anthracycline regimens has justified the continuing search for alternative cardioprotectants to be used in place of, or in combination with, dexrazoxane. To fit into our unifying hypothesis, 'good protectants' should scavenge both oxygen-and lipid-derived species in order to prevent the induction of mechanisms possibly increasing DOXol formation and linking the acute and chronic phases of cardiotoxicity (cf. Fig. 3 ). Moreover, 'good protectants' should directly shield IRPs and other cell constituents from the damaging effects of DOXol-dependent reactions. Vitamin E and N-acetylcysteine probably have too narrow a spectrum of activity to fulfill these requirements, as they act preferentially on either lipid-or oxygenderived species, respectively. This may provide one more clue to the lack of efficacy of these compounds against chronic cardiotoxicity in patients or large animals.
A 'good protectant' has been identified in amifostine (WR2721), a phosphorylated aminothiol that exposes a hyperreactive sulfydryl moiety (WR1065) upon dephosphorylation by membrane-bound alkaline phosphatase (89) . Amifostine dephosphorylation occurs in normal tissues more effectively than in cancer foci, presumably because of 1) higher alkaline phosphatase expression in the capillary endothelium of well-perfused normal tissues, and 2) impaired alkaline phosphatase activity in malignant tissues, reflecting the low pH values found within hypoxic tumor masses (8) . Amifostine can thus afford selective protection by shielding cellular thiols from ionizing radiations (90) or alkylating antineoplastic agents (91) . Drug metabolism studies have indicated that WR1065 can be recovered from cells or whole organs in the form of symmetrical disulfides and both protein and nonprotein mixed disulfides, similar to other thiol-based antioxidants (92) . However, WR1065 can also be recovered in a form of sulfinic/sulfonic derivatives (92), the same that probably form in IRP-1 when DOX-Fe(II) damages critical cysteines (12) . This indicates that WR1065 might have the potential to protect IRPs and perhaps other proteins from oxidation of critical -SH residues. In addition, amifostine is characterized by selective uptake and retention in the heart and has the ability to scavenge oxygen free radicals produced by DOX (93) , leaving the antitumor efficacy of the anthracycline virtually unchanged. Based on these premises and other encouraging results in experimental models (8) , amifostine can be expected to mitigate both acute and chronic cardiotoxicity, proving more versatile than N-acetylcysteine or other thiol-based protectants.
Another cardioprotective approach that would fit well into our unifying hypothesis of cardiotoxicity is based on low mol wt nitroxyl radicals (nitroxides, ϾNϭO•). Due to their chemical stability toward most diamagnetic molecules, nitroxides have long been used in the experimental settings as biophysical probes, spin labels, or contrast agents in nuclear magnetic resonance and EPR imaging (94) . More recently, nitroxides, particularly piperidine derivatives, have been found to protect cells (95) , organs (96) , and whole animals (97, 98) in a number of experimental models of oxidative stress. Such protective effects have been attributed to the ability of the nitroxyl moiety to dismutate O 2 ⅐Ϫ , detoxify semiquinone free radicals, reduce Fe IV ϭO, and terminate radical-chain reactions by direct interaction with alkyl, alkoxyl, and alkylperoxyl radicals (100, and references therein). Recent studies suggest that some of these antioxidant effects might be mediated at least in part by the hydroxylamine (ϾN-OH) resulting from one-electron reduction of nitroxyl (101) .
The ability of nitroxides to intercept such a wide array of free radicals suggests that they might prove better protectants than N-acetylcysteine or vitamin E, as also mentioned for spin traps. Accordingly, the piperidine nitroxide TEMPOL has been reported to afford remarkable protection in an in vitro model of anthracycline-induced acute cardiotoxicity (102) . Two additional considerations may concur to explain this effect. First, substantial amounts of TEM-POL can be detected in subcellular compartments that are critical sites of DOX metabolism and oxidative damage (e.g., mitochondria and sarcoplasmic reticulum) (102) . Second, nitroxides can oxidize Fe(II) to Fe(III) (94, 102) , thereby decreasing the formation of ⅐ OH or equivalent iron complexes from reaction of Fe(II) with H 2 O 2 or oxygen (cf. Section IV). Besides hampering the oxidative damage underlying acute cardiotoxicity, nitroxide oxidation of Fe(II) might interfere with processes occurring during the chronic phase of cardiac damage, such as DOX-Fe(II) inactivation of IRPs and consequent misplacement of unregulated Fe(II) at the Ca 2ϩ release channel of sarcoplasmic reticulum or other cellular sites (cf. Section VI). Thus, the ability to oxidize Fe(II) might enable nitroxides to protect against both acute and chronic events of cardiotoxicity.
Recent studies with TEMPOL have shown that protective interventions with nitroxides may have two additional advantages. First, nitroxides are remarkably more toxic to neoplastic cells than to their normal counterparts; second, TEMPOL is toxic to both wild-type and multidrug resistant tumor cells (103) . Inasmuch as nitroxides per se cannot interfere with DOX-induced double strand breaks and cell survival (104) , these findings suggest that such compounds can improve the therapeutic index of anthracyclines not only by protecting cardiac tissues, but also by imposing their own toxicity on cancer cells. This unexpected observation in cancer cells has been tentatively explained by one-electron oxidation of the nitroxyl moiety of TEMPOL to an oxo-ammonium cation species (ϾN ϩ -O) with the potential to oxidize critical cellular components (100) . The in vivo efficacy of nitroxides might be limited by their too rapid reduction to the corresponding hydroxylamines, which are probably less effective as antioxidants and almost completely devoid of cytotoxic effects on tumor cells. This problem might be solved by adoption of slow-release devices and/or by the recent development of a polynitroxylated form of human serum albumin that reoxidizes hydroxylamine, shifting the equilibrium in favor of nitroxides (105) .
One last approach to cardiac protection might be to decrease the formation of oxyradicals or C-13 metabolites, thus interfering with either or both steps in our tentative scheme (cf. Fig. 3 ). Lessons from 5-iminodaunorubicin indicate that chemical modifications of the quinone moiety decrease the formation of oxyradicals and attenuate cardiotoxicity; however, extracardiac toxicity can unpredictably occur after these manipulations. Attempts to modify the yield of C-13 metabolites have not been pursued so far, but should be given priority in both academic and industrial environments for at least two different reasons. First, C-13 metabolites do not contribute significantly to the antitumor activity of anthracyclines (106) . Drugs inhibiting aldoketo reductases or anthracyclines forming fewer C-13 metabolites should therefore prove useful to prevent cardiac toxicity without affecting tumor response. Second, our scheme suggests that C-13 metabolites are the ultimate and most critical mediators of chronic cardiotoxicity. Decreasing the formation of these metabolites would generate a bottleneck in the process of cardiotoxicity, irrespective of prior contributions from oxyradicals and related oxidative events.
IX. CONCLUSIONS
In this review, we have shown that the role of iron in anthracycline cardiotoxicity may be less obvious than is usually believed. Most popular hypotheses and less-established mechanisms of iron-dependent toxicity have been tentatively reconciled in a unifying framework; clearly, several aspects of this picture are speculative and call for validation by both preclinical and clinical studies. This limitation notwithstanding, we propose that looking at iron from different, but not mutually exclusive, perspectives may provide new routes to design better protectants and/or less toxic anthracyclines.
Note added in proof: For a different picture of the same topic, the reader may want to consult two reviews that appeared while our article was in press [Myers, C. E. (1998 
